Dr Reddy’s announces financial results for Q2 and H1 FY23
EBITDA is at Rs 19.3 billion and the EBITDA margin is 30.6 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Three pharma companies recall products in US
The three pharma companies -- Dr Reddy's Laboratories, Cipla and Aurobindo Pharma -- are recalling different products in the US…
IQVIA and Dr Reddy’s partner for CRM solution
Dr Reddy’s will rollout IQVIA’s OCE application to its entire field force and marketing users in India to drive more meaningful…
Dr Reddy’s Laboratories enters into licensing agreement with Slayback Pharma
The partnership aims to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the US
Dr Reddy’s announce launch of Bortezomib for injection, 3.5 mg single-dose vial in US
Bortezomib for injection is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma and mantle…
Business sustainability through compliance, process excellence and process simplification
As India Parma Inc strives to transform into a more value-led and innovation-driven industry, it has to develop strategic…
Knowledge management in pharma industry- An overview
Narendira Kumar, Associate Director and Site Quality Head, Dr Reddy’s Laboratories, Vizag, drew from his comprehensive expertise…
JB Pharma acquires four paediatric brands from Dr Reddy’s Laboratories
The total covered market size of four brands – Z&D, Pedicloryl, Pecef and Ezinapi combined is Rs 1800 crores
Dr Reddy’s launch generic version of Nexavar (sorafenib) Tablets, 200 mg in US
Sorafenib is a kinase inhibitor used to treat unresectable hepatocellular carcinoma and locally recurrent or metastatic,…
Government panel recommends permission for phase-III trial of Sputnik Light vaccine as booster dose
The DCGI had on 4th February granted emergency use permission to Sputnik Light vaccine in India, subject to certain regulatory…